Laurolactam Market Report 2026-2035: Size, Producers, Pricing and Scenarios to 2047 (CAS 947-04-6)

Description

MARKET KRYSTAL · CAS INTELLIGENCE

LaurolactamMarket Outlook, 2026-2035 forecast; 2036-2047 scenarios

CAS 947-04-6Forecast 2026-2035 forecast; 2036-2047 scenariosPDF + ExcelGlobal + regional

Evidence-led market analysis connecting supply, demand, pricing, trade, participants and commercial opportunities.

Named company coverageEvidence-linked market scopeAnalyst customization
CAS-level scopeThe molecule is followed from feedstocks and production routes through applications and end users.
Named market participantsCompanies, plants, capacity developments and commercial actions are supported by evidence.
Decision-ready deliveryPDF analysis and Excel datasets with scope customization before final delivery.

Market overview

Laurolactam (CAS 947-04-6) is the monomer for polyamide 12 (PA12), a high-performance nylon used in automotive fuel and brake lines, offshore and gas pipes, medical tubing, sports goods and, increasingly, powder-bed 3D printing. It is made from butadiene via cyclododecatriene in a long, complex process, so very few companies produce it. Evonik, with its Marl complex, is the leading producer.

The question this report answers
How much laurolactam does PA12 need as 3D printing, automotive lines and fuel cells grow, and how concentrated is supply?

Market Krystal preliminary estimate (2025)
No published size. Assuming 120-180 kt at USD 3,000-5,000/t, we estimate USD 0.4-0.9 bn (largely captive). Confidence grade C: no reliable published figure; range built from the stated assumptions and narrowed in the full report.

Market dynamics
– Demand: PA12 for automotive fuel and brake lines, 3D printing powders, cables, sporting goods
– Supply: Evonik (Marl) and very few others; large captive share
– Price and margin: butadiene-based cost; specialty pricing
– Regulation: concentration risk shown by past PA12 shortages

Key figures at a glance (third-party, cited)
– Evonik invested EUR 400 mn in a new PA12 complex at Marl, raising its PA12 capacity by more than 50%; first plant completed October 2020 (ChemXplore)
– No reliable standalone market size is published for laurolactam; the report sizes it from PA12 production

Recent developments among key stakeholders
– Sep-Oct 2026: BASF made a non-binding offer for Evonik valued at about EUR 10.3 bn (about EUR 22 per share); Evonik rejected it as too low, BASF may raise it and is courting RAG-Stiftung (about 43% holder); on 22 Oct 2026 BASF pledged no operational dismissals until 2032 in a combination (PlasticsToday)
– 2020-2021: Evonik completed its EUR 400 mn PA12 complex at Marl, raising PA12 capacity by more than 50% (ChemXplore)

What this means for the market
A BASF-Evonik combination would put this product under new ownership or into an antitrust remedy sale. Bidders, banks, competitors and customers all need an independent, product-level view of capacity, share and pricing now.

How published estimates compare
Because almost all laurolactam is used captively to make PA12, merchant-market estimates are rare and unreliable. Market Krystal derives laurolactam demand from PA12 output by end use and maps the very short list of producers.

Strategic scenarios to 2047
– Base: plastics and compounds grow with packaging, automotive, electrical and construction demand; additive volumes follow polymer output.
– Constrained supply: Chinese additive producers dominate volume, so trade measures or plant closures cause regional shortages.
– Technology transition: halogen-free, phthalate-free and recycling-compatible additives take share as regulations and brand targets tighten.
The swing factor for Laurolactam is PA12 demand in 3D printing and automotive lines. Signposts: REACH restrictions, recycling mandates, EV and electronics FR standards, anti-dumping cases.

What this report delivers
Annual volume (tonnes) and value (USD) for 2026-2035, segmented by use: captive PA12 polymerisation vs. merchant sales; pA12 application: automotive lines, oil and gas pipes, 3D printing powders, medical, sports and consumer; region: Europe, Asia, North America. Each segment is backed by a producer capacity table, price benchmarks for 2020-2025 by grade and region, trade-flow analysis and a supplier risk map. Companies assessed include Evonik, Arkema, UBE, EMS-Chemie, Chinese emerging producers. The 2036-2047 outlook uses three explicit scenarios (base, constrained supply and technology transition) rather than a single extrapolated curve.

Who uses this report
Automotive suppliers, 3D printing companies, polyamide producers and investors.

Why our approach is evidence-based
Most CAS-level market listings publish a single number with no audit trail, and we regularly find figures that contradict their own growth rates or exceed the size of the market they sit inside. Market Krystal works the other way round. We start from physical evidence: plant capacities, production and trade data, company disclosures, regulatory texts and price records. We build volume and price separately and only then compute value. Every third-party figure is cited, every Market Krystal estimate is labelled with its method and a confidence grade, and conflicts between sources are shown rather than hidden. Confidence grades: A = two or more independent sources agree, or government or company data; B = one published estimate checked against volumes or prices; C = no reliable published figure, so the range is built from stated assumptions and narrowed in the full report.

Methodology and delivery
Prepared by the Market Krystal Chemicals Research Team. Each report is built around the buyer’s question: after purchase, a short scope confirmation fixes the priority regions, companies and applications, and the report is delivered within 5-7 business days with the Excel model behind every estimate, so buyers can audit and change the assumptions.

The purchased delivery includes the PDF report, Excel datasets and customization around the buyer’s priority region, company set, application or commercial question.

What this research answers

The study connects production routes, named suppliers, applications, regional demand, trade, pricing drivers and commercial opportunities for this CAS number. Detailed estimates and company analysis remain inside the purchased report.

What this research is designed to answer

  • Who produces the molecule, where, and at what supported capacity?
  • How can capacity changes alter regional supply balances?
  • Which feedstocks and operating variables move producer economics?
  • Which applications and end users drive incremental demand?
  • How should buyers approach sourcing and contract decisions?
  • Where are the strongest market-entry and partnership opportunities?

BUILT AROUND YOUR DECISION

Need a specific company, region or customer question answered?

Request the sample and tell us the commercial decision behind your research. We will confirm the relevant scope before delivery.

    In order to understand the detailed research methodology, depth of research, data captured, and story boarding, request us a free sample report for you

    Name

    email

    Contact Number

    Description

      Market Krystal customizes the research output accurately as per your specific business problem related to this industry. Let us know your requirement in detail

      Name

      Email

      Contact Number

      Description

      Single User Licence

      Users

      Restricted to 1 user

      Format

      Excel

      Pre-sell Customization

      Yes

      Free Post-sell Customization

      10% of total Analyst Affort
      multiple User Licence

      Users

      Restricted to 5 users

      Format

      Excel

      Pre-sell Customization

      Yes

      Free Post-sell Customization

      20% of total Analyst Affort

      Reviews

      There are no reviews yet.

      Be the first to review “Laurolactam Market Report 2026-2035: Size, Producers, Pricing and Scenarios to 2047 (CAS 947-04-6)”

      Your email address will not be published. Required fields are marked *

      Share On :